TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23732774

Group type: EXPERIMENTAL
Intervention: Endoscopic cystogastrostomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical cystogastrostomy
Number of subjects: 40
Study: 21218643

Group type: EXPERIMENTAL
Intervention: Phloroglucinol 80 mg daily for 3 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 74
Study: 18581214

Group type: EXPERIMENTAL
Intervention: History of incarceration
Number of subjects: 581
Study: 15390130

Group type: EXPERIMENTAL
Intervention: Dopamine agonists (either in monotherapy or in combination)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control PD patients (not specified how many)
Number of subjects: 202
Study: 12820866

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10763520

Group type: EXPERIMENTAL
Intervention: Contingent Feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Noncontingent Feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Success Conditions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Failure Conditions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Group (Reading Passage)
Number of subjects: 48
Study: 8851613

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day for 3 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg once daily for 3 days)
Number of subjects: 40
Study: 8243814

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3084015

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 104
Study: 31718918

Group type: EXPERIMENTAL
Intervention: Conventional bimaxillary surgery (n=6)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mandibular autorotation (n=7)
Number of subjects: 13
Study: 29351885

Group type: EXPERIMENTAL
Intervention: rTMS + CPT
Number of subjects: 103

Group type: COMPARATOR
Intervention: sham + CPT
Number of subjects: 103
Study: 27105949

Group type: EXPERIMENTAL
Intervention: 1-mm ultra-minimally invasive ultrasound-guided carpal tunnel release
Number of subjects: 92

Group type: COMPARATOR
Intervention: 2-cm blind mini-open carpal tunnel release
Number of subjects: 92
Study: 25728891

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 119

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 119
Study: 22827479

Group type: EXPERIMENTAL
Intervention: SmartClip self‐ligating brackets
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional standard edgewise brackets
Number of subjects: 18
Study: 21668767

Group type: EXPERIMENTAL
Intervention: Fetal blood sampling (FBS) performed according to predefined criteria
Number of subjects: 2827

Group type: EXPERIMENTAL
Intervention: Fetal blood sampling (FBS) not performed according to predefined criteria
Number of subjects: 2827
Study: 18512508

Group type: EXPERIMENTAL
Intervention: Beveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 24 h
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonbeveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 24 h
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Beveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 180 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonbeveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 180 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Indirect composite restorations (prepolymerized Filtek Z250 cemented with Adper Single Bond/Rely X ARC) after 180 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thermal cycling and water storage
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonbeveled restorations
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Beveled restorations
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sound teeth (control group)
Number of subjects: 80
Study: 17157121

Group type: EXPERIMENTAL
Intervention: FEX60/PSE120
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study: 14617226

Group type: EXPERIMENTAL
Intervention: Pramlintide (120 μg bid) + insulin
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo + insulin
Number of subjects: 166
Study: 10766095

Group type: EXPERIMENTAL
Intervention: Woman-specific data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-specific data
Number of subjects: 0
Study: 9042663

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Busulfan (BU) monotherapy
Number of subjects: 0
Study: 1565551

Group type: EXPERIMENTAL
Intervention: Amoxicillin prophylaxis
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Tympanostomy tube insertion
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 3907825

Group type: EXPERIMENTAL
Intervention: Doxorubicin at a dose of 60 mg/m2 every 3 weeks, total dose of 550 mg/m2
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cyclophosphamide at a dose of 1500 mg/m2 every 3 weeks for 1 year
Number of subjects: 32
Study: 31212376

Group type: EXPERIMENTAL
Intervention: Survival entrepreneurship strategies
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Entrepreneurial processes
Number of subjects: 45
Study: 28287920

Group type: EXPERIMENTAL
Intervention: Future alone social exclusion condition
Number of subjects: 253

Group type: COMPARATOR
Intervention: Future belonging condition
Number of subjects: 253

Group type: COMPARATOR
Intervention: No feedback condition
Number of subjects: 253
Study: 27219721

Group type: EXPERIMENTAL
Intervention: 7-layer-coating implant
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard TKA implant
Number of subjects: 120
Study: 24423146

Group type: EXPERIMENTAL
Intervention: Advice plus cognitive behavioural intervention (CBI)
Number of subjects: 701

Group type: COMPARATOR
Intervention: Advice
Number of subjects: 701
Study: 22230474

Group type: EXPERIMENTAL
Intervention: 8 g mushroom powder
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 16 g mushroom powder
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0 g mushroom powder (control)
Number of subjects: 10
Study: 20124517

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg daily)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily)
Number of subjects: 131
Study: 17671288

Group type: EXPERIMENTAL
Intervention: Adjunctive modafinil (mean dose, 177 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Adjunctive modafinil
Number of subjects: 85
Study: 16081235

Group type: EXPERIMENTAL
Intervention: Patient-centered communication style
Number of subjects: 159

Group type: COMPARATOR
Intervention: Disease-centered communication style
Number of subjects: 159

Group type: COMPARATOR
Intervention: Emotion-centered communication style
Number of subjects: 159
Study: 11815983

Group type: EXPERIMENTAL
Intervention: Silver-coated polyurethane catheters (BactiGuard; Metacot, Stockholm, Sweden), n = 120
Number of subjects: 233

Group type: COMPARATOR
Intervention: Uncoated standard polyurethane catheters (Cavatheter, Fresenius AG, Bad Homburg, Germany), n = 113
Number of subjects: 233
Study: 9972860

Group type: EXPERIMENTAL
Intervention: Trimethaphan (peripheral nicotinic receptor antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Usual brand of cigarette
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Denicotinized tobacco cigarettes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicotine-injected cigarettes
Number of subjects: 12
Study: 7726398

Group type: EXPERIMENTAL
Intervention: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during hypothermia (34 degrees C)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during normothermia (37 degrees C)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg administered as an intravenous bolus during hypothermia (34 degrees C)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Atracurium 0.5 mg/kg administered as an intravenous bolus during normothermia (37 degrees C)
Number of subjects: 6
Study: 1319523

Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg) administered before injection of LA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group without sedation
Number of subjects: 20
Study: 6719042

Group type: EXPERIMENTAL
Intervention: Aspirin (Bayer) 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reumyl (Hässle) 500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premaspin (Lääke) 500 mg
Number of subjects: 0
Study: 30837595

Group type: EXPERIMENTAL
Intervention: ENGAGE (structured play-based intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Triple P (behavior management)
Number of subjects: 60
Study: 30171370

Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 186

Group type: COMPARATOR
Intervention: CinnoVex
Number of subjects: 186
Study: 27006189

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 7576

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 7576
Study: 25269900

Group type: EXPERIMENTAL
Intervention: Preoperative group (before OLT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postoperative group (after OLT)
Number of subjects: 20
Study: 22701531

Group type: EXPERIMENTAL
Intervention: Access to the web portal
Number of subjects: 96

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study: 21134048

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (20 U)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 17933438

Group type: EXPERIMENTAL
Intervention: Diet enriched in eicosapentanoic acid (EPA), gamma-linolenic acid (GLA), vitamins A, C, and E
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control diet similar in macronutrient composition
Number of subjects: 100
Study: 16277797

Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control
Number of subjects: 104
Study: 11840418

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (taxane and platinum compound)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line treatments (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New combination regimens (gemcitabine, topotecan, encapsulated doxorubicin with carboplatin plus paclitaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological approaches (drugs interfering with angiogenesis, matrix metalloproteinases, signal transduction pathways)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with a biologic agent for six cycles followed by chronic maintenance biologic therapy
Number of subjects: 0
Study: 9933701

Group type: EXPERIMENTAL
Intervention: Intraoperative chemotherapy with MMC (10 mg/patient) and UFT 300 mg/day (P1 group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: UFT 600 mg/day (P2 group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: UFT 300 mg/day (P0 group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: UFT 300 mg/day (H1 group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: UFT 600 mg/day (H2 group)
Number of subjects: 78
Study: 7767538

Group type: EXPERIMENTAL
Intervention: Topical fluticasone nasal spray (200 micrograms daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2306061

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of ranitidine (50 mg every 8 hours and 75 mg every 12 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of ranitidine (75, 150, and 300 mg every 24 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6455095

Group type: EXPERIMENTAL
Intervention: 1% clindamycin hydrochloride
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate
Number of subjects: 358

Group type: COMPARATOR
Intervention: Hydroalcoholic vehicle (placebo)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: 1% clindamycin hydrochloride and 1% clindamycin phosphate
Number of subjects: 358
Study: 30676479

Group type: EXPERIMENTAL
Intervention: Urinary Tract Dilation classification system
Number of subjects: 243

Group type: COMPARATOR
Intervention: Society for Fetal Urology scale
Number of subjects: 243
Study: 27616745

Group type: EXPERIMENTAL
Intervention: 1‐DAY sodium nitrate supplementation (1097 mg sodium nitrate providing 800 mg nitrate per day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 6‐DAY sodium nitrate supplementation (1097 mg sodium nitrate providing 800 mg nitrate per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: PLA (5 days placebo and 1 day sodium nitrate supplementation)
Number of subjects: 17
Study: 26805529

Group type: EXPERIMENTAL
Intervention: APRV group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26

Group type: COMPARATOR
Intervention: APRV group and Control group
Number of subjects: 26
Study: 23837918

Group type: EXPERIMENTAL
Intervention: CHOCAF (25 g carbohydrate + 100 mg caffeine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO (25 g carbohydrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PL (non-caloric placebo)
Number of subjects: 12
Study: 21880336

Group type: EXPERIMENTAL
Intervention: IFN beta-1a, 44 mcg sc three times weekly (tiw)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 19606472

Group type: EXPERIMENTAL
Intervention: Donepezil (5-10 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 17348082

Group type: EXPERIMENTAL
Intervention: Two-stage allocation rule for binary response
Number of subjects: 0
Study: 14998944

Group type: EXPERIMENTAL
Intervention: Metformin (MET) 1.5 to 2.55 g/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 42
Study: 11591562

Group type: EXPERIMENTAL
Intervention: High-intensity residential exercise training program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 9498432

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 96
Study: 8059918

Group type: EXPERIMENTAL
Intervention: 28 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Number of subjects: 40
Study: 3189721

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (after reinstitution of treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (withdrawal)
Number of subjects: 20
Study: 31663640

Group type: EXPERIMENTAL
Intervention: CT (Conditioning Training)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CT with feedback
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 49
Study: 29710164

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily) + Aspirin (100 mg once daily)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 500
Study: 28755042

Group type: EXPERIMENTAL
Intervention: Standard care plus home visiting (n=99)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard clinic care (n=104)
Number of subjects: 203
Study: 25271201

Group type: EXPERIMENTAL
Intervention: Yoga therapy (3-month yoga course of group classes and home practice)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal medical care (Control)
Number of subjects: 61
Study: 24053631

Group type: EXPERIMENTAL
Intervention: Family meetings intervention
Number of subjects: 192

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 192
Study: 21812923

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 1.5 mg/day
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 3.0 mg/day
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) with standard dose cyclosporine (SD‐CsA)
Number of subjects: 2004
Study: 19302885

Group type: EXPERIMENTAL
Intervention: Consultation using genetic information about obesity
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Standardized consultation without genetic information
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group without any intervention
Number of subjects: 411
Study: 16495245

Group type: EXPERIMENTAL
Intervention: Telbivudine 25 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 100 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine 800 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telbivudine (all doses)
Number of subjects: 0
Study: 12605972

Group type: COMPARATOR
Intervention: Conventional radiotherapy (64 Gy in 32 fractions within 6.5 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy (55 Gy in 20 fractions within 4 weeks)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatment schedules (Conventional and Hypofractionated)
Number of subjects: 120
Study: 11092290

Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE 901)
Number of subjects: 619

Group type: COMPARATOR
Intervention: NPH human insulin
Number of subjects: 619
Study: 9314855

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) administration (150 micrograms intra-arterial bolus, with or without a 10 mg GTN patch for 24 hours)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Saline placebo administration
Number of subjects: 83
Study: 8444719

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine (5-HT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study: 3097726

Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine during stress
Number of subjects: 12

Group type: COMPARATOR
Intervention: Stress alone (placebo)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.0 mg nicotine alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest + placebo (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stress + nicotine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rest + nicotine
Number of subjects: 12
Study: 31563909

Group type: EXPERIMENTAL
Intervention: Harmonized Cognitive Assessment Protocol (HCAP) cognitive test battery, including in-person interviews lasting approximately 1 hour with the respondent and 20 minutes with an informant.
Number of subjects: 3496
Study: 30242809

Group type: COMPARATOR
Intervention: NPSR1 (rs324981) T/T genotype
Number of subjects: 600

Group type: COMPARATOR
Intervention: NPSR1 (rs324981) AT genotype
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall coping style
Number of subjects: 600
Study: 26810768

Group type: EXPERIMENTAL
Intervention: AD+CAD
Number of subjects: 257

Group type: COMPARATOR
Intervention: AD-only
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: AD+CAD (among APOE ε4 allele carriers)
Number of subjects: 257
Study: 25551436

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 281
Study: 22775412

Group type: EXPERIMENTAL
Intervention: Atorvastatin lactone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Atorvastatin acid
Number of subjects: 52
Study: 20104219

Group type: EXPERIMENTAL
Intervention: Long-term low-dose peginterferon alpha-2a (90 microg/week)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 129
Study: 18779512

Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 microg/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (healthy participants)
Number of subjects: 19
Study: 16137507

Group type: EXPERIMENTAL
Intervention: Red wine (250 ml daily, Cabernet Sauvignon)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (abstinence from alcoholic beverages)
Number of subjects: 20
Study: 12366475

Group type: EXPERIMENTAL
Intervention: Acute exercise (bicycle ergometer, >6 mM blood lactate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (minimal activity, no lactate elevation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study: 10480671

Group type: EXPERIMENTAL
Intervention: Fenfluramine (oral dl-fenfluramine)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 8722429

Group type: EXPERIMENTAL
Intervention: Automated telephone system for monitoring and counseling
Number of subjects: 267

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 267
Study: 1760767

Group type: EXPERIMENTAL
Intervention: Calcium oxalate
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Spinach calcium (intrinsic label)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Spinach calcium (extrinsic label)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Milk calcium (alone)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Milk calcium (co-ingested with spinach)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Spinach calcium (co-ingested with milk)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Labeled oxalate (co-fed with labeled milk)
Number of subjects: 34
Study: 6127219

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Metoprolol 100 mg bid
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30209126

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4850

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4850

Group type: EXPERIMENTAL
Intervention: Apixaban and Warfarin
Number of subjects: 4850